PTCB High-Alert Medications and Error Prevention study guide

What this topic actually asks of you

Domain 3 of the PTCE is Patient Safety and Quality Assurance (23.75% of the exam). Three of its six knowledge areas sit in this topic:

High-alert/risk medications and look-alike/sound-alike (LASA) medications

That is KA 3.1;

Error prevention strategies (e.g., prescription or medication order to correct patient, Tall Man lettering, separating inventory, leading and trailing zeros, bar code usage, limit use of error-prone abbreviations)

KA 3.2; and

Types of prescription errors (e.g., incorrect dose, quantity, patient, drug, route of administration)

KA 3.5, which the outline marks with its calculation footnote — "Some or all of this statement reflects calculation-based knowledge." Together these are the knowledge areas about stopping harm before it reaches a patient: which drugs hurt most when they go wrong, which names look and sound alike, the small habits that catch a wrong dose, and how the errors that do happen get sorted by severity.

One idea runs through all of it. A pharmacist or technician cannot be more careful on demand. What actually prevents harm is a system: a drug that everyone treats as dangerous, a name that looks different from its twin, a zero written where a zero belongs, a second person who checks. Every fact below is one of those systems written down, and the exam asks you to recognize which one applies.

The two hardest lines in this topic are both about who publishes what. The high-alert lists are ISMP's, and there are two of them (community/ambulatory and acute care). The Tall Man letter lists are published by both the FDA and ISMP, and they are not the same list — the FDA's is a short list the agency asks manufacturers to adopt, and ISMP's is a longer one that is not FDA-approved. A question that asks "who publishes this" is testing exactly that split.

This guide links out, it does not repeat. The abbreviation lists belong to the order interpretation and sig guide, and the mL-only oral liquid device rules belong to administration, equipment and supplies. Both are summarized in one line below and linked, so this guide can spend its words on what is not there.

High-alert medications

The ISMP definition

A high-alert medication is not simply a dangerous drug. It is a drug where an error is unusually damaging. ISMP's own definition, printed on both of its lists, is:

High-alert medications are drugs that bear a heightened risk of causing significant patient harm when they are used in error. Although mistakes may or may not be more common with these drugs, the consequences of an error are clearly more devastating to patients.

Read the second sentence twice, because it is the whole point and the exam's favorite distinction. A high-alert drug is not the drug most often involved in errors; it is the drug where the same mistake costs more. A tenfold overdose of a statin is uncomfortable. A tenfold overdose of insulin, or of a concentrated potassium solution, is fatal. So the list is not a ranking of error frequency at all — it is a ranking of consequence, and it exists so that a pharmacy can put its scarcest resource, a second look, exactly where a slip does the most damage.

Two consequences follow, and both are exam material:

• A high-alert drug gets safeguards that other drugs do not, even though the drug itself may be ordinary — insulin is common, cheap and safe when dosed right.
• When an error reaches a patient, a high-alert drug is more likely to land in the severe categories of the NCC MERP index, which is why 3.1 and 3.5 sit beside each other in this topic.

The two lists, and their editions

ISMP does not publish one list. It publishes a family of them, one per care setting, because the drugs a community pharmacy dispenses are not the drugs an intensive care unit runs:

Two facts about the lists that a question can turn on:

• ISMP's acute-care list changes on ISMP's own schedule. The 2024 edition's headline change was the addition of tranexamic acid injection — an antifibrinolytic used to control bleeding, including postpartum hemorrhage — after error reports showed it stored with, and mixed up with, look-alike anesthetic vials. ISMP's 2023 survey also found rising recognition that agents such as potassium phosphate for injection and oxytocin are high alert. A question can be built on what changed in 2024, not only on the list as a whole.
• The lists are not a fixed curriculum. ISMP first compiled six high-alert medications in 1989, and those original drugs are still on the list; it has grown by evidence since. So "which drug is on ISMP's high-alert list" is a question about a published list with an edition, and the honest answer names the list and the year.

How a list is laid out. ISMP's community/ambulatory list prints under two headings — a short list of Classes/Categories of Medications and a short list of Specific Medications. The specific drugs are the ones no class covers, which is why carBAMazepine, lamoTRIgine and methotrexate (nononcologic) sit under Specific Medications while insulins, opioids and oral sulfonylureas are classes. The distinction the exam draws is between a class-level entry (every oral hypoglycemic, every opioid formulation) and a drug-level entry (one named drug whose class is not otherwise high alert).

The acute-care list is not the community list. It exists for a setting where different drugs are used, and where the same drug arrives by a different route. A technician moving between an outpatient pharmacy and a hospital sees two different lists, and a question that names a setting wants that setting's list.

The safeguards ISMP names

The lists only matter because of what a pharmacy does with them. ISMP prints the strategies beside each list. The safeguards are:

• Standardizing the prescribing/ordering, storage, preparation, dispensing and administration of these medications;
• Improving access to information about the drugs;
• Limiting access to high-alert medications (where the drug physically is, and who can reach it);
• Using auxiliary labels and automated alerts, so the warning rides on the product and pops on the screen;
• Employing redundancies — a second check, automated or independent — the safeguard a technician meets every shift.

Notice what is not on the list: "be more careful". Every safeguard is a change to the system, and that is the frame these questions are written in.

Look-alike, sound-alike names

The pairs and why they collide

Look-alike/sound-alike (LASA) medications are drugs whose names or packages can be mistaken for one another. ISMP's List of Confused Drug Names — which ISMP also calls its LASA list — collects the pairs that have actually been reported. ISMP describes it this way:

ISMP's List of Confused Drug Names contains look-alike and sound-alike (LASA) name pairs, of medications that have been published in the ISMP Medication Safety Alert! and the ISMP Medication Safety Alert! Community/Ambulatory Care Edition through February 28, 2019.

A pair gets onto the list for a reason, and the reason is the exam question. Five causes cover almost every pair:

• The spelling is similar and the ending is shared. glipiZIDE and glyBURIDE look alike and share the same -ide ending; Tall Man lettering capitalizes the differing blocks (glipiZIDE / glyBURIDE), because a reader skimming a shelf label reaches the middle and the tail last.
• The names are sound-alikes. traMADol and traZODone differ by one syllable in the middle; a phone order read aloud makes them the same word.
• One is a second form of the same drug. Adderall and Adderall XR, or Wellbutrin SR and Wellbutrin XL — same active ingredient, different release, and the difference is the whole dose.
• The strengths or sizes sit next to each other. One name in two strengths on one shelf is a LASA risk with no spelling difference at all.
• The packaging looks alike. Two manufacturers' boxes, one color and one layout.

Common outpatient pairs, as ISMP lists them in its February 28, 2019 edition: acetaminophen / acetaZOLAMIDE; glipiZIDE / glyBURIDE; traMADol / traZODone; hydrALAZINE / hydrOXYzine; chlorproMAZINE / chlorproPAMIDE; clomiPHENE / clomiPRAMINE; predniSONE / prednisoLONE; risperiDONE / rOPINIRole; buPROPion / busPIRone; Aciphex / Accupril; Actonel / Actos; Adderall / Adderall XR; Adderall / Inderal; Advair / Advicor; Alkeran / Leukeran; Wellbutrin SR / Wellbutrin XL; Xanax / Tenex; Xanax / Zantac; ZyrTEC / Zantac; ZyrTEC / ZyPREXA; Zetia / Zestril; Zestril / Zegerid; Zocor / Cozaar; TRENtal / TEGretol; valACYclovir / valGANciclovir; vinBLAStine / vinCRIStine.

A few of those entries name a brand that is no longer marketed in the US — Advicor, the Tenex brand and Zantac — which is itself the lesson: the list records the confusions that were reported, and a pair is not retired the moment a product leaves the shelf. Treat those three as 2019-edition names.

The shape of those pairs is the lesson: they are usually one letter or one syllable apart, which is why they survive a glance. A near-twin name only becomes a hazard when both are within reach of the same pair of eyes.

Other LASA strategies

ISMP prints its own strategies beside the list, and they are the ones the exam quotes:

• Use both the brand and the generic name on prescriptions and labels.
• Include the purpose of the medication on the prescription — "for blood pressure" separates two names the letters cannot.
• Configure computer selection screens so look-alike names do not appear consecutively in a dropdown.
• Change the appearance of look-alike product names to draw attention to their differences — which is what Tall Man lettering is.
• Add shelf separation, so the two drugs are not reached for from the same spot.

Tall Man lettering

Who publishes the lists

Tall Man lettering (TML) uses uppercase letters to make two similar names stop looking similar. The FDA defines it precisely:

Tall man lettering (TML) is a technique that uses uppercase lettering to help differentiate look-alike drug names. Starting on the left side of a drug name, TML highlights the differences between similar drug names by capitalizing dissimilar letters (e.g., vinBLAStine versus vinCRIStine and CISplatin versus CARBOplatin).

Two organizations publish Tall Man lists, and they are not the same list:

• The FDA publishes the FDA List of Established Drug Names Recommended to Use Tall Man Lettering. FDA started the Name Differentiation Project in 2001 to review postmarketing reports of name-pair confusion. When FDA decides TML is the right fix, it asks the manufacturer to revise the label and then updates its list — so the FDA list is short, and every entry on it is a name FDA has acted on.
• ISMP publishes its own, longer list — Look-Alike Drug Names with Recommended Tall Man Letters — which ISMP states is not an official list approved by FDA and is intended for voluntary use by practitioners and drug-technology vendors. ISMP's list also carries brand names, because a brand can collide with another brand just as easily as a generic can.

That split is the exam's question. Who publishes the list — FDA or ISMP — changes the answer, because only the FDA list carries the force of a label change, and only ISMP's carries recommendations ISMP made without FDA approval.

How the letters are chosen is the last piece, and ISMP has written it down. ISMP follows a tested methodology, the CD3 rule: work from the left of the name and capitalize every character to the right once two or more dissimilar letters are met; then work from the right and return two or more letters both names share to lowercase. When that cannot be applied — because the names share nothing on the right — capitalize the central part of the word instead. If the rule produces letters that are still too similar, or unreadable, ISMP considers an alternative.

The FDA list, character for character

This is the FDA list as the agency publishes it. The capitalization is the point, so it is reproduced exactly — each row names the established drug and the name it is confused with:

Three things to read off that table, because each one is a question:

• The uppercase block sits in a different place in different names. HYDROmorphone capitalizes the first block and glipiZIDE capitalizes the tail. There is no rule that says "capitalize the second half".
• Two entries stand alone. HYDROmorphone and mitoXANTRONE are on the list to separate them from a neighbor that is not on the list, which is why you cannot assume every entry comes in a pair.
• A row can hold three names, as the methylprednisolone row does — and a triple is not three pairs.

Error prevention

Leading and trailing zeros

Two punctuation rules, both about a decimal point that can be missed:

• Always write a leading zero before a decimal point: 0.5 mg, never .5 mg. Read without the point, .5 mg is 5 mg — a tenfold error.
• Never write a trailing zero after a decimal point: 5 mg, never 5.0 mg. Read across a dropped point, 5.0 mg is 50 mg.

The rule is asymmetric for a reason: a zero that protects the decimal point is required, and a zero that invites a misreading is forbidden. The same logic governs the error-prone abbreviation list in the order interpretation and sig guide — U for units, QD, MS, the trailing-zero entry — so that list is summarized here rather than repeated: this guide ships the two zero rules; that guide ships the lists.

Verbal orders and read-back

A verbal (or telephone) order is the highest-risk way a prescription arrives, because nothing is written down by the person who gave it. The safeguard is read-back: the person receiving the order writes it down, then reads the whole order back to the prescriber — drug, strength, dose, route, frequency — and gets an explicit confirmation before it is entered. Read-back catches the error dictation creates and transcription cannot see: the drug that sounded like another drug (tramadol / trazodone).

Adjacent failure modes the exam draws on: illegible handwriting (the classic reason for a read-back at the counter) and e-prescribing dropdown errors, where the prescriber picks the right drug name and the wrong strength because two entries sit next to each other in a menu — the same geometry as a LASA shelf.

Two patient identifiers

The Joint Commission's National Patient Safety Goal NPSG.01.01.01 (for hospitals, renumbered NPG.01.01.01 in the 2026 National Performance Goals; the two-identifier rule is unchanged) requires an organization to use at least two patient identifiers when providing care, treatment and services — and the identifiers must be things the patient is or carries, not the room or the bed, both of which change. The Joint Commission does not name which two identifiers to use; it requires two. A common acceptable pair is name and date of birth.

The rule matters at the counter because of what it prevents: a bag handed to the wrong person, which is a wrong-patient error however correct everything inside the bag is. "It was on the will-call shelf with her name on it" is not identification; asking the patient to state the date of birth is.

Barcode scanning and the NDC

Barcode scanning at fill works by checking a product identifier against the prescription — in practice the National Drug Code (NDC), the number that names the exact product (labeler, product, package size). The scan does not verify the patient, the dose or the directions; it verifies that the package in the hand is the package the order calls for. The NDC half of that belongs to the NDC, lot and expiration guide, so it is cross-linked here, not repeated.

The rights of medication use

Every pharmacy uses a version of the "rights", and the outline does not fix a set. The core five appear in every version:

• Right patient — confirmed with two identifiers.
• Right drug — confirmed against the order, and by name (which is where LASA vigilance lives).
• Right dose — confirmed with the zero rules and a dose-range check.
• Right route — confirmed against the dosage form ordered (an oral solution is not a topical).
• Right time — confirmed against the frequency and the sig.

Most lists add right documentation, and many add right reason/indication, right to refuse and right assessment. Learn the five plus documentation, and learn why each exists rather than the count — a question can name any of them as the missing "right" in a scenario.

Error-prone situations

The conditions that produce errors are predictable, and naming them is the skill:

• Interruptions and high volume. A counting tray abandoned mid-count is a wrong-strength error waiting.
• Fatigue and long shifts — the errors cluster at the end of them.
• Similar packaging and same-name shelf neighbors (the LASA case).
• Unfamiliar drugs — a technician who does not know a drug cannot notice it is wrong.
• Pediatric dose calculations, where the arithmetic runs by weight rather than a fixed dose.
• mg versus mL in oral liquids — the confusion the mL-only device rule exists to remove (see administration, equipment and supplies).

Types of prescription errors

The NCC MERP index, A to I

Errors are classified by outcome, not by who made them. The NCC MERP Index for Categorizing Medication Errors is that standard: NCC MERP adopted it in 1996 and its current version is the 2022 edition, and ISMP has implemented it inside the ISMP Medication Errors Reporting Program database. NCC MERP states the index "considers factors such as whether the error reached the patient and, if the patient was harmed, and to what degree" — which is the same as saying it sorts an event into a category from A to I along three bands:

The three bands sit on top of those nine letters: A is no error, B to D are error and no harm, E to H are error and harm, and I is death. Learn the letters first — a question asks for a letter, and the band is what the letter means.

NCC MERP's own definition of the thing being classified, because every other word here depends on it: "A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer" — and it continues into the places such an event can start: professional practice, products, procedures and systems, including prescribing, order communication, labeling, packaging, nomenclature, compounding, dispensing, distribution, administration, education, monitoring and use. Two words in that sentence do the work: preventable (so the event is one a system could have stopped) and control of (a stage of the medication-use process, not only the moment a patient swallows a tablet).

The quotes are NCC MERP's, from the NCC MERP Index for Categorizing Medication Errors (adopted 1996; current version 2022). NCC MERP also defines the three words the bands turn on: harm is "Impairment of the physical, emotional, or psychological function or structure of the body and/or pain resulting therefrom"; monitoring is "To observe or record relevant physiological or psychological signs"; and an intervention "May include change in therapy or active medical/surgical treatment".

Two exam-grade lines come straight out of that table. Category B is the near miss — "an error occurred but the error did not reach the patient" — which is why a pharmacy that counts only "errors that reached a patient" is measuring the wrong thing. And the band labels repeat: B, C and D are all "error, no harm" even though B never reached the patient and D needed an intervention to preclude harm.

Abnormal doses

Three dose errors are common enough and damaging enough to name separately:

• The tenfold decimal error — a misplaced or dropped point, the error the zero rules exist to prevent: 0.5 mg read as 5 mg, or 5 mg read as 50 mg.
• Milligrams for micrograms — the metric slip. The abbreviation half is in the sig guide; the arithmetic half is that 1,000× is invisible on a label.
• Daily for weekly — methotrexate is dosed weekly for non-oncologic use, and a daily reading is fatal. That is why methotrexate sits on the high-alert list as a specific medication: the drug and strength can be right while the frequency is wrong.

Learning from errors

RCA and FMEA

Two tools, and the exam tests the direction of each:

• Root cause analysis (RCA) is reactive — it happens after a serious event and asks why the system allowed it, not who was careless.
• Failure mode and effects analysis (FMEA) is proactive — it happens before anything goes wrong and asks how this process could fail and how bad the failure would be.

Same goal, opposite direction: RCA looks backward at an event that happened; FMEA looks forward at a process that has not failed yet.

Just culture and near-miss reporting

Just culture is the position that people should not be punished for errors and at-risk behavior while reckless behavior is still held to account. It matters to a technician for a practical reason: errors are only reported where reporting is safe. If a near miss gets a technician fired, the next near miss goes unwritten and the pharmacy learns nothing.

Near-miss reporting is the payoff — ISMP describes its Medication Errors Reporting Program (the ISMP MERP) as "the only national voluntary practitioner medication error reporting program", and NCC MERP's index is what makes those reports comparable. A near miss that is written down is a defect the system can fix before a patient meets it.

Numbers, letters and lists to know

Pairs to keep apart

How to practice this

• Read the free high-alert medications practice set and, on each item, name the safeguard first — list, LASA, zero rule, identifier, read-back, barcode, index category — because the safeguard picks the answer.
• Write the two zero rules out as sentences until they are automatic: leading required, trailing forbidden.
• Learn one pair per confusion cause, not the whole list: one late-spelling pair (glipiZIDE / glyBURIDE), one sound-alike (traMADol / traZODone), one same-drug pair (Adderall / Adderall XR).
• Fix the three bands of the NCC MERP index: A is not yet an error, B is a near miss, E–I is harm.
• Work the order interpretation and sig guide for the abbreviation lists, and the administration, equipment and supplies guide for the mL-only device rule.

Where to go next

• Next topic — intervention reporting and infection control
• The exam itself — the passing score, how many questions, and what makes the PTCB exam hard.

This topic sits inside Domain 3 — Patient Safety and Quality Assurance, 23.75% of the exam — the outline's own weight, and PTCB publishes no per-knowledge-area split.

PTCE® is a registered trademark of the Pharmacy Technician Certification Board (PTCB). Elk Ridge Academy is not affiliated with or endorsed by PTCB.